Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 14/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18864135 | 1.00 | DRD4 (0.43) | DRD4DRD2MCHR1DRD3CD274 | |
| SCHEMBL18864137 | 1.00 | DRD4 (0.43) | DRD4DRD2MCHR1DRD3CD274 | |
| SCHEMBL18864042 | 0.94 | MCHR1 (0.46) | DRD4DRD2MCHR1DRD3CD274 | |
| SCHEMBL18864046 | 0.94 | MCHR1 (0.46) | DRD4DRD2MCHR1DRD3CD274 | |
| SCHEMBL18890852 | 0.88 | KDM4D (0.42) | DRD4DRD2 | |
| SCHEMBL18890845 | 0.83 | MCHR1 (0.41) | DRD4DRD2MCHR1DRD3CD274 | |
| SCHEMBL18864029 | 0.82 | POLB (0.39) | CD274 | |
| SCHEMBL18864026 | 0.82 | POLB (0.39) | CD274 | |
| SCHEMBL18864070 | 0.79 | PTGDR2 (0.36) | DRD2DRD3TSHR | |
| SCHEMBL18864116 | 0.79 | PTGDR2 (0.36) | DRD2DRD3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145005-A1 | KINASE INHIBITOR | THE UNIVERSITY OF TOKYO (JP) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145005-A1 | KINASE INHIBITOR | PIM3, PIM1, PIM2 | DRD4 4675/4885DRD2 4629/4885MCHR1 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.